The global patent disputes between mRNA vaccine manufacturers have once again set the patent community buzzing. While GSK launched several lawsuits at the UPC against Moderna, BioNTech and Pfizer in July, BioNTech's pending acquisition of GSK's cooperation partner CureVac has shifted the landscape. CureVac has now reached an agreement with BioNTech and Pfizer to end its patent proceedings.\n\nAfter BioNTech announced its plans to acquire German competitor CureVac, a settlement seemed inevitable. Last Friday, CureVac, BioNTech and its cooperation partner Pfizer announced they would end their patent dispute in the USA. Subject to the successful completion of the acquisition, all other proceedings between the parties concerning mRNA-based vaccines will also conclude.\n\nCureVac initiated the dispute by suing BioNTech in Germany over patents and several utility models in summer 2022. BioNTech and its US partner Pfizer also sued CureVac in the US.\n\nA BioNTech press release states that the Mainz-based company and Pfizer \"entered into agreements with CureVac and an affiliate of GSK to resolve the pending patent litigation in the United States, and set a framework for resolving patent litigation and allegations of patent infringement between BioNTech, Pfizer and CureVac outside the U.S. (subject to closing of the Acquisition).\"\n\nBioNTech and Pfizer will receive a non-exclusive licence from CureVac to manufacture, use, import into the US and sell mRNA-based COVID-19 and influenza products. This licence will extend worldwide upon completion of the acquisition.\n\nAs compensation, BioNTech will pay GSK $370 million and a 1% royalty on US sales of the licensed products. CureVac and GSK are linked by a cooperation in mRNA vaccines, which both companies recently restructured. Unlike BioNTech and Moderna, neither company successfully brought a Covid-19 vaccine to market.\n\nFollowing the acquisition’s completion, BioNTech will pay an additional $130 million to GSK and a 1% royalty on rest-of-world sales. Meanwhile, Pfizer has agreed to reimburse BioNTech for $80 million and half of claimed royalties.\n\nDespite the pending acquisition, CureVac will also benefit financially from the deal. BioNTech will pay CureVac $370 million and a 1% royalty on US sales. After completion of the acquisition, BioNTech will pay another 1% royalty on rest-of-world sales.\n\nDespite the settlement between CureVac and BioNTech/Pfizer, GSK announced over the weekend that it would continue its litigation against BioNTech and Pfizer in the US and Europe, stating that \"the settlement does not impact GSK’s enforcement of its own patents against Pfizer and BioNTech in the U.S. and in Europe\".\n\nIn April 2024, GSK sued BioNTech and Pfizer in the District Court of Delaware for infringement of two patents. In July 2025, the company filed two lawsuits with the Unified Patent Court. The first infringement suit relates to EP 4 226 941 and EP 4 066 856 (case ID: ACT_32285/2025). The second action alleges infringement of EP 2 590 626 (case ID: ACT_32214/2025).\n\nGSK filed both lawsuits at the local division in The Hague. They target various European entities of both companies and contain detailed long-arm jurisdictional requests.\n\nDutch patent judges have a tradition of granting cross-border injunctions. Presiding judge Edger Brinkman and Margot Kokke are handling the cases. Stefan Schilling from the Hamburg local division is the third judge.\n\nIn addition to the UPC actions, GSK filed an infringement action in Ireland against both opponents based on the same patents (case ID: H.P.2025.0003802).\n\nAccording to the UPC case search, Tjibbe Douma and Carlos van Staveren are assisting GSK in the lawsuits. Their law firm Bird & Bird has long-standing relationships with both GSK and its cooperation partner CureVac. Bird & Bird represented CureVac against BioNTech and Pfizer in Germany and the UK. A German team also represented GSK in a UPC case against Pfizer over RSV vaccines. The dispute settled in April.\n\nBird & Bird is also conducting the Irish proceedings against BioNTech and Pfizer.\n\nAccording to the UPC case search, BioNTech has retained Tess Waldron and Joel Coles from UK firm Powell Gilbert. Penny Gilbert, Peter FitzPatrick and newly hired patent attorney Charlotte Malley complete the team. The firm also represents BioNTech in the Irish proceedings through its Dublin office.\n\nPowell Gilbert has a close relationship with the German biotech company. The firm is involved in most of BioNTech’s ongoing disputes — whether coordinating the disputes or conducting the UK proceedings.\n\nBioNTech also relies on the German practice of Hoyng ROKH Monegier led by Christine Kanz in various proceedings. For example, in a UPC lawsuit brought by Promosone. The firm also has an experienced pharmaceutical team in the Netherlands should BioNTech decide to engage local advisors for the UPC proceedings against GSK.\n\nHowever, Powell Gilbert represents only BioNTech against GSK. It is not yet publicly known which law firm Pfizer will choose. Taylor Wessing is likely to be a strong candidate. The law firm regularly represents Pfizer in patent cases through its London and Dutch teams. Dutch partner Wim Maas, for example, represents Pfizer in the Dutch mRNA cases against Moderna.\n\nPfizer also relies on other law firms in other disputes. Marks & Clerk, for example, represented Pfizer together with Clifford Chance in the battle with GSK over RSV vaccines. A Clifford Chance team represents Pfizer in the UPC dispute with Promosone. Unlike Taylor Wessing, however, neither law firm has Dutch patent litigators.\n\nGSK’s litigation campaign extends beyond BioNTech and Pfizer. In July, the company launched a major offensive against leading Covid-19 vaccine manufacturers. With Bird & Bird’s support, the company filed two lawsuits against Moderna at the local division The Hague. The patents-in-suit are the same as in the cases against BioNTech and Pfizer. Once again, Brinkmann, Kokke and Schilling make up the judicial panel (case IDs: ACT_32173/2025 and ACT_32120/2025).\n\nThe UPC case search names Thomas Wolter and Matthew Naylor of Mewburn Ellis as main representatives for Moderna. Both patent attorneys are also registered as UPC representatives. The patent attorney firm already represents Moderna in an EPO opposition against GSK’s EP 941 and has filed several patent applications for Moderna at the European Patent Office.\n\nHowever, the firm does not have an office in the Netherlands. Moderna also maintains close relationships with Freshfields here. Partner Rutger Kleemans coordinates the dispute with BioNTech and Pfizer, for example. An international Freshfields team also represents Moderna in defending two UPC lawsuits filed by Arbutus Biopharma and Genevant Sciences.\n\nIt is therefore likely that Moderna will also involve a Freshfields team in the new dispute with GSK. However, JUVE Patent has not yet received confirmation of this.\n\nThe UPC is steadily becoming an attractive venue for pharmaceutical litigation. Merz recently filed the first SPC claim against Viatris here. However, lawsuits concerning mRNA patents are increasingly becoming central, with BioNTech and Moderna particularly in the spotlight.\n\nA total of seven UPC lawsuits now feature the technology, which generated substantial sales for BioNTech and Moderna during the coronavirus pandemic and is set to be used for future influenza drugs.\n\nMost lawsuits reached the UPC in 2025, including two each from GSK against BioNTech, Pfizer and Moderna. Arbutus Biopharma and Genevant Sciences also filed lawsuits against Moderna at the local division The Hague in April.\n\nThe Hague is now hearing six of the seven mRNA proceedings at the UPC. Promosone filed its lawsuit against BioNTech and Pfizer at the Düsseldorf local division at the end of 2024.

mRNA patent wars kick into higher gear during dog days of summer

Global patent disputes among mRNA vaccine manufacturers intensify as GSK continues legal actions against BioNTech and Pfizer in the U.S. and Europe, despite a settlement between CureVac, BioNTech, and Pfizer to end their U.S. patent litigation. The settlement includes a non-exclusive license from CureVac to BioNTech and Pfizer for manufacturing and selling mRNA-based COVID-19 and influenza products, with financial compensation involving $370 million and royalties. BioNTech will pay GSK $370 million and 1% royalties on U.S. sales, an additional $130 million and 1% royalties on rest-of-world sales post-acquisition, while Pfizer will reimburse BioNTech $80 million and half of claimed royalties. CureVac also receives $370 million and 1% royalties on U.S. sales, plus 1% on rest-of-world sales after acquisition. GSK maintains separate litigation against BioNTech, Pfizer, and Moderna in the Unified Patent Court and Ireland, citing that the settlement does not affect its enforcement of its own patents. The legal battles involve multiple law firms, including Bird & Bird, Powell Gilbert, and Freshfields, with key judges in The Hague overseeing proceedings. The UPC is emerging as a central venue for pharmaceutical patent disputes, particularly in mRNA technology, with seven related lawsuits now active.